Epigenetic Age Measures to Predict COVID-19 Symptom Progression and Severity
Epigenetic Age Measures to Predict COVID-19 Symptom Progression and Severity
批准号:
10158592
负责人:
Morgan Elyse Levine
金额:
$13.94万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-03-01 至 2021-05-31
关键词:
Admission activityAdultAgeAgingAllelesBiologicalBiological AgingBiological MarkersCOVID-19COVID-19 pandemicCardiovascular DiseasesCellsCenters for Disease Control and Prevention (U.S.)Cessation of lifeChronic DiseaseChronic Kidney FailureChronic Obstructive Airway DiseaseChronologyClinicClinicalCommunitiesDNA MethylationDataDevelopmentDiabetes MellitusDiseaseEnsureEpigenetic ProcessEtiologyFutureGeneral PopulationGenomeGeroscienceGrantHealthHeart DiseasesHigh PrevalenceHome environmentHybridsHypertensionImmunocompetenceIncidenceIndividualIndividual DifferencesInfectionLiftingLiver diseasesLung diseasesMachine LearningMeasurementMeasuresMedicalMethodsMethylationMolecularMorbidity - disease rateNatureOrganismPathogenicityPatientsPatternPersonsPhysiologicalPopulationPopulation ResearchPredispositionProcessProxyRiskRisk FactorsRisk stratificationRunningSamplingSensitivity and SpecificitySeveritiesSiteSpeedSupport SystemSymptomsTechniquesTechnologyTestingTimeTissuesTriageUnited StatesVentilatorVirusVirus DiseasesWorkage relatedbasebisulfitecell typeclinical applicationclinical riskcoronavirus diseasecostcost effectivegenome-widehuman very old age (85+)molecular markermortalitymortality riskmultidisciplinarynovelolder patientpredictive markerpreservationresilienceresponsesocialtransmission processtrend
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
The risk of fatality and/or severe complications due to COVID-19 infection is strongly age
dependent. Data from the CDC suggests that those ages 85 and older have predicted mortality rates
that is 100-fold higher than for those under the age of 50 and currently, 8 out of 10 COVID-19 deaths
in the United States were in adults age 65 or older. While the exact etiology underlying this age
disparity is unknown, evidence suggests that vulnerability may be due to changes that occur as a
function of the aging process. This is further evidenced by the pattern of increased vulnerability
among persons with pre-existing diseases of aging—cardiovascular disease, diabetes, COPD,
chronic kidney disease, liver disease—suggesting that it isn't just chronological age that determines
risk, but rather, biological age.
In recent years, our group has helped develop some of the most robust biomarkers available,
namely the epigenetic clocks. These measures estimate biological age in a sample based on DNA
methylation levels at hundreds to thousands of CpG sites across the genome. Not only do epigenetic
clocks track with age in diverse tissues and cell types, but discrepancies between epigenetic age and
actual age have also been shown to predict risk of mortality and incidence of major chronic disease,
including those which appear to be major risk factors for COVID-19. However, in order for these
measures to be informative for assessing COVID-19 risk clinically, or in the general population, 1)
they need to be re-optimized to capture the aspects of biological aging specific to COVID-19
susceptibility, and 2) advances in technology need to be made to ensure lower costs and rapid
turnaround.
This proposal aims to build on our team's multidisciplinary strengths to develop and validate a
targeted, lab-developed, readily-available test to predict COVID-19 symptomology and mortality risk.
If successful, this test will have widespread applications—from informing triage and treatment
decisions in the clinic, to guiding social and pollical decisions when it comes to lifting “stay-at-home”
orders for certain individuals.
期刊论文(9)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1210/clinem/dgaa081
发表时间:
2020-02
期刊:
The Journal of clinical endocrinology and metabolism
影响因子:
--
作者:
[R. Thurston;J. Carroll;M. Levine;Yuefang Chang;C. Crandall;J. Manson;L. Pal;L. Hou;A. Shadyab-A.-Shad]
通讯作者:
R. Thurston;J. Carroll;M. Levine;Yuefang Chang;C. Crandall;J. Manson;L. Pal;L. Hou;A. Shadyab-A.-Shad
DOI:
10.1111/acel.13376
发表时间:
2021-06
期刊:
Aging cell
影响因子:
7.8
作者:
[Kuo CL, Pilling LC, Liu Z, Atkins JL, Levine ME]
通讯作者:
Levine ME
DOI:
10.1093/gerona/glab060
发表时间:
2021-07-13
期刊:
The journals of gerontology. Series A, Biological sciences and medical sciences
影响因子:
--
作者:
[Kuo CL, Pilling LC, Atkins JL, Masoli JAH, Delgado J, Tignanelli C, Kuchel GA, Melzer D, Beckman KB, Levine ME]
通讯作者:
Levine ME
DOI:
10.7554/elife.59201
发表时间:
2020-11-12
期刊:
eLife
影响因子:
7.7
作者:
[Levine M, McDevitt RA, Meer M, Perdue K, Di Francesco A, Meade T, Farrell C, Thrush K, Wang M, Dunn C, Pellegrini M, de Cabo R, Ferrucci L]
通讯作者:
Ferrucci L
DOI:
10.1371/journal.pmed.1002718
发表时间:
2018-12-01
期刊:
PLoS medicine
影响因子:
15.8
作者:
[Liu, Zuyun, Kuo, Pei-Lun, Levine, Morgan]
通讯作者:
Levine, Morgan
AMYLOIDOGENIC INDUCTION OF CELLULAR SENESCENCE IN ALZHEIMER'S DISEASE
-
批准号:10222562
-
项目类别:
-
资助金额:$40.42万
-
财政年份:2020
-
负责人:Morgan Elyse Levine
-
依托单位:
AMYLOIDOGENIC INDUCTION OF CELLULAR SENESCENCE IN ALZHEIMER'S DISEASE
-
批准号:10044065
-
项目类别:
-
资助金额:$41.2万
-
财政年份:2020
-
负责人:Morgan Elyse Levine
-
依托单位:
Molecular mechanisms and social constructs: How genes and environment regulate the rate of aging
-
批准号:9551142
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2017
-
负责人:Morgan Elyse Levine
-
依托单位:
Molecular mechanisms and social constructs: How genes and environment regulate the rate of aging
-
批准号:9755278
-
项目类别:
-
资助金额:$23.53万
-
财政年份:2017
-
负责人:Morgan Elyse Levine
-
依托单位:
海外基金